Psychotic Disorders - Iran

  • Iran
  • Revenue in the Psychotic Disorders market is projected to reach US$36.16m in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of -10.58%, resulting in a market volume of US$23.12m by 2028.
  • In global comparison, most revenue will be generated in the United States (US$2,257.00m in 2024).
  • In relation to total population figures, per person revenues of US$35.95 are generated in 2024.

Key regions: Germany, France, United States, Australia, Japan

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Psychotic Disorders market in Iran is witnessing significant growth and development due to various factors. Customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors all contribute to the current state of the market.Customer preferences in the Psychotic Disorders market in Iran are shifting towards more effective and personalized treatment options. Patients are increasingly seeking treatments that not only alleviate symptoms but also address the underlying causes of their disorders. This has led to a growing demand for innovative therapies and medications that target specific psychotic disorders. Additionally, there is a rising preference for non-pharmacological interventions, such as cognitive-behavioral therapy and psychosocial support, as patients seek holistic approaches to managing their conditions.Trends in the market reflect the global advancements in the understanding and treatment of psychotic disorders. Iran is witnessing an increase in research and development activities focused on developing novel therapies and medications. Pharmaceutical companies are investing in clinical trials and collaborations with local healthcare providers to bring cutting-edge treatments to the Iranian market. This trend is driven by the growing recognition of the burden of psychotic disorders and the need for more effective and accessible treatment options.Local special circumstances also play a role in the development of the Psychotic Disorders market in Iran. The country has a relatively high prevalence of mental health disorders, including psychotic disorders. This has created a significant demand for diagnostic tools, medications, and therapeutic interventions. However, there are challenges in terms of access to mental healthcare services, especially in rural areas. Efforts are being made to address this issue by expanding the mental health infrastructure and improving the availability of specialized healthcare professionals.Underlying macroeconomic factors further contribute to the growth of the Psychotic Disorders market in Iran. The country has experienced economic growth in recent years, leading to an increase in healthcare spending. This has allowed for greater investment in mental health services and the development of the Psychotic Disorders market. Additionally, the government has implemented policies to promote mental health awareness and improve access to care, further driving the market's growth.In conclusion, the Psychotic Disorders market in Iran is developing rapidly due to changing customer preferences, global trends, local special circumstances, and underlying macroeconomic factors. The market is witnessing a shift towards personalized and holistic treatment options, driven by the growing recognition of the burden of psychotic disorders. Efforts are being made to improve access to mental healthcare services, and the government is investing in the development of innovative therapies. With continued investments and advancements, the Psychotic Disorders market in Iran is expected to grow further in the coming years.

Methodology

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

Overview

  • Revenue
  • Patients
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)